“Lenacapavir could face competition from another investigational treatment, leronlimab, currently being developed by CytoDyn (OTCMKTS: CYDY). Also in the mix is ViiV Healthcare’s cabotegravir, an integrase inhibitor. Cabotegravir-based options are projected to generate the bulk of sales in the injectables segment, says GlobalData.“



https://www.thepharmaletter.com/article/gilea...g-sunlenca